paclitaxel has been researched along with Thromboembolism in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aldrich, C; Bahary, N; Braiteh, F; Bullock, AJ; Chondros, D; Harris, WP; Hendifar, AE; Hingorani, SR; Jiang, P; Khelifa, S; Oberstein, PE; Pu, J; Ritch, PS; Seery, TE; Sigal, DS; Wang-Gillam, A; Wu, W; Zalupski, MM; Zheng, L | 1 |
| Bosch, DJ; Hospers, GA; Mul, VE; Plukker, JT; Van Dalfsen, QA | 1 |
| Capelan, M; Lote, H; Mohammed, K; Papadimitraki, E; Redana, S; Ring, A; Sharp, A | 1 |
| Baber, U; Clemmensen, P; Dangas, GD; Feit, F; Gersh, BJ; Guagliumi, G; Mehran, R; Ohman, EM; Pocock, SJ; Schoos, MM; Stone, GW; Witzenbichler, B; Yu, J | 1 |
| Goense, L; Haj Mohammad, N; Meijer, GJ; Mook, S; Ruurda, JP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; van Rossum, PSN; van Vulpen, M | 1 |
| Asbell, SO; Bae, K; Kerlin, KJ; Michalski, JM; Pienta, KJ; Rajan, R; Rosenthal, SA; Sandler, HM; Sobczak, ML | 1 |
| Belinsky, SA; Dahlberg, SE; Fitzgerald, TJ; Hoang, T; Johnson, DH; Mehta, MP; Schiller, JH | 1 |
| Coulon Sfairi, MA; Dalenc, F; Delva, R; Espié, M; Hardy-Bessard, AC; Kockler, L; Lortholary, A; Monnier, A; Pavlyuk, M; Pierga, JY; Pivot, X; Serin, D; Veyret, C | 1 |
| Ahn, TH; Choi, KR; Han, SH; Kang, WC; Shin, EK | 1 |
| Batchelor, WB; Buchbinder, M; Dubois, CL; Fitzgerald, PJ; Gammon, R; Garg, J; Hasselblad, V; Hermiller, JB; Kereiakes, DJ; Krucoff, MW; Lansky, AJ; Mehran, R; O'Shaughnessy, CD; Petersen, JL; Schofer, J; Simonton, CA; Turco, MA; Verheye, S; Wijns, W | 1 |
| Jones, KD | 1 |
6 trial(s) available for paclitaxel and Thromboembolism
| Article | Year |
|---|---|
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enoxaparin; Female; Fibrinolytic Agents; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Thromboembolism; Time Factors | 2018 |
Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes.
Topics: Aged; Antineoplastic Agents, Phytogenic; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Europe; Female; Follow-Up Studies; Heparin; Hospital Mortality; Humans; Incidence; Intraoperative Complications; Male; Middle Aged; New South Wales; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Sex Distribution; Sex Factors; ST Elevation Myocardial Infarction; Survival Rate; Thromboembolism; Ticlopidine; Time Factors; United States | 2016 |
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-ris
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Estramustine; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Paclitaxel; Prostatic Neoplasms; Thromboembolism | 2009 |
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Micrometastasis; Neoplasm Staging; Paclitaxel; Survival Rate; Thalidomide; Thromboembolism | 2012 |
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Hemorrhage; Humans; Hypertension; Middle Aged; Neutropenia; Paclitaxel; Proteinuria; Taxoids; Thromboembolism; Young Adult | 2012 |
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Chromium Alloys; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Polymers; Risk; Thromboembolism; Ticlopidine; Time Factors | 2008 |
5 other study(ies) available for paclitaxel and Thromboembolism
| Article | Year |
|---|---|
Increased risk of thromboembolism in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carboplatin; Chemoradiotherapy; Endosonography; Esophageal Neoplasms; Esophagectomy; Humans; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Radiotherapy Dosage; Thromboembolism | 2014 |
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Incidence; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pulmonary Embolism; Retrospective Studies; Risk Factors; Sentinel Lymph Node Biopsy; Stroke; Taxoids; Thromboembolism; Venous Thrombosis | 2016 |
Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease Progression; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Netherlands; Paclitaxel; Propensity Score; Thromboembolism | 2017 |
Acute myocardial infarction caused by late stent thrombosis after deployment of a paclitaxel-eluting stent.
Topics: Acute Disease; Coronary Angiography; Drug Delivery Systems; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Stents; Thromboembolism; Time Factors | 2005 |
Thromboembolic events with paclitaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Paclitaxel; Radiation-Sensitizing Agents; Thromboembolism | 1996 |